Safety of Atrovent® CFC-free inhaler: respiratory events reported from an observational cohort study in England

Abstract

The results of this study suggest effect modification of risk as a result of prior Atrovent CFC MDI use. Overall, Atrovent CFC-free MDI appeared to be reasonably well tolerated in the immediate postmarketing period and the safety profile appeared similar to that of the CFC formulation.